Canton Strategic Holdings, Inc. (CNTN)
2.14
+0.06
(+2.88%)
USD |
NASDAQ |
Sep 03, 12:16
Canton Strategic Holdings Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.0318 |
| June 30, 2025 | 0.9099 |
| March 31, 2025 | -0.6384 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.0268 |
| June 30, 2024 | 0.0299 |
| March 31, 2024 | 0.045 |
| December 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0461 |
| June 30, 2023 | 0.1049 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.4622 |
| September 30, 2021 | -0.3016 |
| June 30, 2021 | -0.3187 |
| March 31, 2021 | -0.3645 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 564.57M |
| Total Liabilities (Quarterly) | 109.67M |
| Shareholders Equity (Quarterly) | 454.90M |
| Current Ratio | 15.70 |
| Net Debt Paydown Yield | 0.05% |